Attralus to Present New Data on Its Amyloidosis Portfolio at the 2022 International Symposium on Amyloidosis

Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today

Related Keywords

Germany ,Heidelberg ,Baden Wüberg ,San Francisco ,California ,United States ,Arnt Kristen ,Ashutosh Wechalekar ,Luke Heagle ,Christophe Sirac ,Alan Stuckey ,Manasi Balachandran ,Emily Martin ,Olivier Clerc ,J Steve Foster ,Neue Universit ,R Eric Heidel ,Gregory Bell ,Marina Ramirez Alvarado ,Morie Gertz ,International Symposium On Amyloidosis ,University College London ,Research Fellow Amyloidosis Program ,International Society Of Amyloidosis ,Attralus Inc ,University Hospital Heidelberg Universit ,University Of Tennessee Research Foundation ,Cancer Theranostics Program Session ,University Of Limoges ,University Of Tennessee Graduate School Medicine ,Cancer Theranostics Program ,Tennessee Graduate School ,International Society ,Chief Medical Officer ,International Symposium ,Assistant Professor ,Jonathan Wall ,Distinguished Professor ,Basic Research ,Treatment Targets ,Unmet Need ,Anti Amyloid Therapy ,University College ,University Hospital Heidelberg ,Associate Professor ,Research Director ,Cancer Theranostics ,Research Associate ,Systemic Amyloidosis ,Amyloid Diagnostic ,Tennessee Research ,Serum Amyloid Protein ,Looking Statements ,Attralus ,To ,Present ,New ,Data ,Son ,Its ,Amyloidosis ,Portfolio ,Hat ,The ,2022 ,International ,Symposium ,